[G24-09] Polatuzumab vedotin (relapsed or refractory DLBCL) – Addendum to Project A23-140
Last updated 20.06.2024
Project no.:
G24-09
Commission:
Commission awarded on 07.05.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
DOI:
https://dx.doi.org/10.60584/G24-09
| Project no. | Title | Status |
|---|---|---|
| A23-140 | Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-06-20 A G-BA decision was published.